PIK3CA and hepatocellular carcinoma: Here, we investigated the antitumor effect of H2-18 in combination with the pan-PI3K inhibitor GDC-0941 on both trastuzumab-sensitive (BT-474, SKBR-3) and -resistant (HCC-1954, HCC-1419) breast cancer cell lines.